The Humira in Ocular Inflammations Taper (HOT) Study

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Noninfectious uveitis (NIU) is a chronic inflammatory eye condition.
• Adalimumab is a common biologic therapy for achieving remission in NIU.
• Tapering adalimumab requires careful consideration to prevent disease recurrence.

Purpose of the Study:

• To identify factors influencing relapse risk in noninfectious uveitis patients after adalimumab dose reduction.
• To evaluate the impact of patient demographics and treatment parameters on uveitis recurrence post-adalimumab tapering.

Main Methods:

• Retrospective multicenter study involving 328 patients with NIU treated with adalimumab.
• Data collected included patient demographics, NIU type, disease history, remission duration, and adalimumab tapering schedule.
• Statistical analysis identified predictors of uveitis recurrence rate.

Main Results:

• Recurrence was observed in 39.6% of patients, with younger patients (mean age 29.4 years) experiencing higher rates.
• Faster adalimumab tapering schedules were significantly associated with increased recurrence risk (HR=1.23).
• Longer periods of inactivity before tapering (mean 100.8 weeks) were linked to a lower recurrence rate (HR=0.97).

Conclusions:

• Patient age, race, and duration of remission on adalimumab are critical factors during dose tapering.
• A slow, gradual tapering strategy for adalimumab is recommended to minimize noninfectious uveitis relapse.
• Personalized tapering protocols considering individual patient factors may improve long-term outcomes.